Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck & Co.
Biotech
Merck pays $588M for bispecific to defend Keytruda’s kingdom
The outlay, plus up to $2.7 billion in milestones, has secured Merck global rights to LaNova Medicines’ PD-1xVEGF bispecific antibody.
Nick Paul Taylor
Nov 14, 2024 7:45am
Arcus drops promising data on HIF-2a candidate in kidney cancer
Oct 24, 2024 2:48pm
Merck snaps up preclinical DNA biotech for $1.3B biobucks
Oct 23, 2024 7:05am
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks
Oct 21, 2024 5:06am
With trial win, Merck looks to take on Sanofi, AZ in RSV
Oct 17, 2024 6:00pm
Merck signs $1.9B deal to explore fibroblast therapies
Oct 8, 2024 8:55am
